Blood Cancer News and Research

RSS

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Incyte Corporation announced today additional symptom improvement and quality of life (QoL) results from COMFORT-I, a randomized, double-blinded, placebo-controlled Phase III trial of Incyte's JAK1 and JAK2 inhibitor, ruxolitinib, in patients with myelofibrosis (MF).

13 Jun 2011

LLS announces four new Academic Concierge partnerships for cancer drug development

With more than 320 academic science research grants currently in its portfolio, The Leukemia & Lymphoma Society (LLS) has made it a priority to help move promising discoveries more quickly from the laboratory to clinical trial and to patients with cancer.

7 Jun 2011

Incyte seeks FDA marketing approval of ruxolitinib for myelofibrosis

Incyte Corporation announced today that it has submitted a New Drug Application (NDA) for its lead investigational compound, ruxolitinib (INCB18424), to the US Food and Drug Administration (FDA).

6 Jun 2011

TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

Emergent BioSolutions Inc. announced today that it has acquired from TenX BioPharma, Inc. the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas.

6 Jun 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte Corporation announced today results from the global, pivotal Phase III clinical program of ruxolitinib in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

6 Jun 2011

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

3 Jun 2011

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

On May 29, 2011 XTL has announced that its rHuEPO drug which is currently in preparations for phase 2 clinical trial, has been granted an Orphan-drug designation by the US Food and Drug Administration (FDA) for treatment of Multiple Myeloma blood cancer.

2 Jun 2011

Oak Point students raise $42,474.24 to combat cancer

Penny by penny, students at Oak Point Intermediate School in Eden Prairie, MN, raised an incredible $42,474.24 through Pennies for Patients, making them the top fundraiser nationwide in The Leukemia & Lymphoma Society's School & Youth Programs.

18 May 2011

New study sheds light on origins of myeloid leukemia

A new study by the NYU Cancer Institute, an NCI-designated cancer center, sheds light on the origins of myeloid leukemia, a type of blood cancer that affects children and adults.

13 May 2011

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

The Multiple Myeloma Research Foundation and Astellas Pharma Global Development, Inc. today announced that they have entered into a joint collaboration for the clinical development of OSI-906 in patients with relapsed multiple myeloma.

6 May 2011

Researchers develop new gene therapy technique for CGD treatment

Researchers have developed an effective technique that uses gene therapy on stem cells to correct chronic granulomatous disease in cell culture, which could eventually serve as a treatment for this rare, inherited immune disorder, according to a study published in Blood, the Journal of the American Society of Hematology.

29 Apr 2011

NCI, ASH, AMEH join to improve care for patients with AML

A workshop being held today will serve as the launch of a unique project that unites the American Society of Hematology, the Agrupaci-n Mexicana para el Estudio de la Hematolog-a, and the National Cancer Institute in pursuit of a common goal: improving the care of patients with acute myeloid leukemia.

11 Apr 2011

Report shows a continued decline in diagnoses, deaths for many types of cancers

Once again, the Annual Report to the Nation on the Status of Cancer shows a continued decline in diagnoses and deaths for many types of cancers. This encouraging news can be attributed primarily to preventive measures such as cessation of smoking and improved diet, and early detection.

2 Apr 2011

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Glenmark Pharmaceuticals announces the discovery and initiation of IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR 401, an anti-CD19 monoclonal antibody. GBR 401 is developed completely in-house by Glenmark's Biologics Research Centre located in Switzerland.

1 Apr 2011

Glasgow Professor discusses about new approach for CML treatment at UK conference

Speaking at the UK National Stem Cell Network conference in York later today, Professor Tessa Holyoake from the University of Glasgow will discuss a brand new approach to treating chronic myeloid leukaemia in which a small number of cancer cells persist despite effective therapy thus preventing cure.

31 Mar 2011

MMRF hails new publication of multiple myeloma genome analysis in Nature journal

The Multiple Myeloma Research Foundation today hailed a new publication in Nature as a major step forward in the organization's efforts to advance a personalized medicine approach in multiple myeloma.

24 Mar 2011

New insights into multiple myeloma research

Scientists have unveiled the most comprehensive picture to date of the full genetic blueprint of multiple myeloma, a form of blood cancer. A study of the genomes from 38 cancer samples has yielded new and unexpected insights into the events that lead to this form of cancer and could influence the direction of multiple myeloma research.

24 Mar 2011

Sequencing mouse cancer genome reveals mutations driving cancer in humans

Scientists who pioneered sequencing the genomes of cancer patients to find novel genetic changes at the root of the disease now have turned their attention to a laboratory workhorse — a mouse.

24 Mar 2011

Oncologists to discuss treatment of blood cancer in elderly

Top oncologists are meeting in Rome today to discuss the treatment of blood cancer in the elderly, with the aim of driving widespread change to ensure equality of care for everyone, whatever their chronological age.

19 Mar 2011

Experts to present latest information on multiple myeloma at Patient Symposium

The Multiple Myeloma Research Foundation and the John Theurer Cancer Center at Hackensack University Medical Center, member of the Multiple Myeloma Research Consortium, will host the MMRF Clinical Insights in Multiple Myeloma Patient Symposium on Saturday, April 2 in Short Hills, NJ from 9:00am-3:30pm.

18 Mar 2011

Blood Cancer News and Research

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

LLS announces four new Academic Concierge partnerships for cancer drug development

Incyte seeks FDA marketing approval of ruxolitinib for myelofibrosis

TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

Oak Point students raise $42,474.24 to combat cancer

New study sheds light on origins of myeloid leukemia

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

Researchers develop new gene therapy technique for CGD treatment

NCI, ASH, AMEH join to improve care for patients with AML

Report shows a continued decline in diagnoses, deaths for many types of cancers

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Glasgow Professor discusses about new approach for CML treatment at UK conference

MMRF hails new publication of multiple myeloma genome analysis in Nature journal

New insights into multiple myeloma research

Sequencing mouse cancer genome reveals mutations driving cancer in humans

Oncologists to discuss treatment of blood cancer in elderly

Experts to present latest information on multiple myeloma at Patient Symposium

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News